The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer

Abstract

BACKGROUND:

Cisplatin-based chemotherapy and radiotherapy are the most commonly used treatments for small cell lung cancer (SCLC). However, despise initially dramatic response, the response duration of SCLC patients is variable and resistance to chemo- and radio-therapy inevitably develops.

OBJECTIVE:

The aim of the study is to investigate the role of Bcl-2 family proteins in predicting SCLC sensitivity to cisplatin treatment, and to identify the potential sensitizer of cisplatin or ratiation treatment in SCLC.

METHODS:

We collected cisplatin sensitivity data from public available database, and evaluated its possible association with mRNA or protein expression of Bcl-2 family members in SCLC cell lines.

RESULTS:

The IC ${}_{50}$ value of cisplatin was significantly correlated with the ratio of Bcl-2/Bim mRNA expression in 33 SCLC cell lines ( $P=$ 0.041) as well as the ratio of Bcl-2/Bim protein expression in 7 SCLC cell lines ( $P=$ 0.0252). Furthermore, a BH3-mimetic ABT-263 was found to be able to sensitize SCLC cells to cisplatin or radiation. The synergistic and additive antitumor activity of ABT-263 combined with cisplatin or radiation was associated with the enhanced apoptosis, which may be caused by the disruption of Bcl-2 binding to Bim by ABT-263.

CONCLUSIONS:

Our study indicates that the ratio of Bcl-2/Bim could be a SCLC response predictor to cisplatin, and ABT-263 addition could be an effective strategy to improve the activity of chemo- or radio-therapy in SCLC.

Keywords

Small cell lung cancer Bcl-2 Bim ABT-263 cisplatin radiation

1. Introduction

Small cell lung cancer (SCLC) is a clinically very aggressive lung cancer and less than 7% of SCLC patients survive more than 5 years [1]. Although SCLC patients have initially high response to chemo- and radio-therapy, the response duration is variable and relapse inevitably develops due to therapeutic resistance. SCLC patients who relapse $>$ 90 days after first-line chemotherapy are classified into sensitive response, and relapse $<$ 90 days are classified into resistant response and relapse $<$ 45 days are classified into refractory response [2]. Therefore, it is important to identify therapeutic response predictors and develop chemo- and radio-sensitizers in SCLC to improve patients’ survival.

Pharmacogenomic strategy provides an approach to develop predictors of drug sensitivity by using integrative analysis of gene expression profiling dataset and drug sensitivity dataset [3]. Currently, the drug sensitivity and gene expression profiling of SCLC cell lines are available in the Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE) databases [4, 5]. The Bcl-2 family proteins are critical regulators of apoptosis induced by chemo- or radio-therapy. The Bcl-2 family anti-apoptotic proteins (Bcl-2, Bcl-xL and Mcl-1) are frequently over-expressed in cancer cells, and confer cellular chemo- and radio-resistance [6]. In SCLC, up-regulation of Bcl-2 increased resistance to cisplatin, a widely used chemotherapeutic drug for the treatment of SCLC [7]. Moreover, the Bcl-2 family pro-apoptotic BH3-only proteins (Bim, Bid, Puma and Noxa) are also critical for initiating apoptosis by activating Bax and Bak, but the induction of apoptosis can be impeded by the interactions between the Bcl-2 family anti-apoptotic proteins and pro-apoptotic proteins. Thus, the ratio between Bcl-2 family anti- and pro-apoptotic proteins is an important determinant of cell survival and cell death [8]. In the study, we firstly examined whether SCLC response to cisplatin was associated with the ratio of Bcl-2 family anti-apoptotic and pro-apoptotic proteins by mining public available databases.

Interestingly, we found that SCLC cell lines with higher ratio of Bcl-2/Bim were significantly correlated with the resistance to cisplatin. The data promoted us to test the hypothesis that a BH3-mimetic ABT-263, which disrupts the interaction of Bcl-2 and Bim, is able to enhance the antitumor activity of cisplatin or radiation in SCLC cells.

2. Materials and methods

2.1 Materials

ABT-263 and cisplatin were purchased from Selleck chemical (Shanghai, China). ABT-199 was purchased from MCE (Shanghai, China). ABT-263 was dissolved in DMSO (Sigma-Aldrich, Saint Louis, MO, USA) to prepare a 10 mM stock solution. Cisplatin was dissolved in PBS (Cellgro, Manassas, VA, USA) to prepare a 5 mM stock solution. Antibodies against PARP, Bcl-2, Mcl-1, Bim were from Cell Signaling Technology, Danvers, MA, USA. $\beta$ -actin antibody was from TransBionovo, Beijing, China. The siRNA against human Bim as well as its negative control siRNA were purchased from Cell Signaling Technology (Danvers, MA, USA).

2.2 Cell lines and cell culture

The human SCLC cell lines H82, H526, DMS79, H69, H1963, H446 and H196 were maintained in RPMI1640 media (Cellgro, Manassas, VA, USA) supplemented with 10% FBS (ExCell Bio, Shanghai, China) and 1% penicillin/streptomycin (Gibco, Life Technologies, Grand Island, NY, USA) in a humidified incubator at 37 ${}^{\circ}$ C in 5% CO ${}_{2}$ .

2.3 X-ray irradiation

SCLC cells were exposed to radiation at a dose of 2 or 4 Gy using X-RAD 320 Biological Irradiator (Precision X-Ray, North Branford, CT, USA). For the combination treatment of radiation and ABT-263, SCLC cells were exposed to radiation after treated with ABT-263 for 2 hours.

2.4 Cell proliferation assay

SCLC cells were plated in 96-well culture plates. After 24 hours, cells were subjected to the treatment of DMSO control, cisplatin, radiation, ABT-263, cisplatin/ABT-263 combination and radiation/ABT-263 combination for 72 hours. After treatment, cell viability was measured by using Cell Titer-Glo Luminescent assay (Promega, Madison, WI, USA) according to the manufacturer’s instructions. Luminescence was measured in a multi-label plate reader (Envision PerkinElmer, USA). Data were normalized to DMSO control and represented by the mean $\pm$ SEM.

2.5 Colony formation assay

For suspension cells (H526 and H69), cells were plated in 60 mm dishes and incubated for 24 hours. Cells were then treated with DMSO control, cisplatin, radiation, ABT-263, cisplatin/ABT-263 combination and radiation/ABT-263 combination for 24 hours. After treatment, 1.25 $\times$ 10 ${}^{3}$ cells in 0.5 ml of RPMI1640 containing 10% (v/v) FBS and 0.33% (w/v) agarose were overlaid onto bottom agar consisting of 0.5 ml of RPMI1640 containing 10% (v/v) FBS and 0.5% (w/v) agarose in a 24-well culture plate. The cells were then incubated at 37 ${}^{\circ}$ C in 5% CO ${}_{2}$ for up to 3 weeks. Colonies were photographed, and colonies containing $>$ 50 cells were counted. For adherent cells (H446), 1 $\times$ 10 ${}^{3}$ cells were plated in 60 mm dishes. After 24 hours, cells were treated with DMSO control, cisplatin, radiation, ABT-263, cisplatin/ABT-263 combination and radiation/ABT-263 combination for 24 hours. The cells were then washed with PBS twice and cultured for up to 2 weeks. Colonies were visualized by crystal violet staining, and colonies with a diameter $>$ 200 $\mu$ M were counted.

2.6 Annexin V apoptosis analysis

The treated cells were stained with FITC Annexin V and PI using a FITC Annexin V Apoptosis Detection Kit (BD Pharmingen, San Diago, CA, USA). The stained samples were subjected to flow cytometry analysis by FACS Calibur (BD Pharmingen, San Diago, CA, USA), and then analyzed by FlowJo software (BD Pharmingen, Ashland, OR, USA).

2.7 Western blot

After treatment, western blot was performed using specific antibodies following the procedure as described previously [9]. For quantification of western blot data, band intensities were quantified using ImageJ software.

2.8 Immunoprecipitation (IP)

After treatment, cells were lysed with immunoprecipitation lysis buffer (250 mM NaCl, 50 mM Tris-HCl pH 7.4, 0.5% Triton X-100, 10% glycerol) and subject to IP analysis as describe previously [10].

2.9 Analysis of combination index

The additivity or synergy of drug combination was determined quantitatively using the combination index (CI) method of Chou and Talalay [11]. CI was calculated using the formula: CI $=$ D1/D ${}_{X1}$ $+$ D2/D ${}_{X2}$ , in which D1 and D2 are the doses used to achieve a specific growth inhibition when two drugs combined, and D ${}_{X1}$ and D ${}_{X2}$ are individual drug doses needed to achieve similar growth inhibition. CI $<$ 1 indicates synergy, whereas CI $=$ 1 indicates additivity.

2.10 Bim siRNA treatment

H69 cells (2 $\times$ 10 ${}^{5}$ ) were seeded onto 6-well plates and incubated for 24 hours. Cells were then transfected with Bim siRNA or control siRNA using Effectene Transfection Reagent (QIAGEN, Hilden, Germany). One days after transfection, one part of transfectants was replated onto 96-well plate and was treated with DMSO, ABT-263, cisplatin, radiation or their combination for 72 hours, and then cell viability was measured by CellTiter-Glo Luminescent assay. Two days after transfection, other part of transfectants was collected for western blot to check whether Bim was knocked down.

2.11 Statistical analysis

All data were analyzed using PRISM5 Software (GraphPad Software, Inc., La Jolla, CA, USA). Statistical analysis was performed using an unpaired t-test. $P$ value $<$ 0.05 was considered statistically different. The correlation of cisplatin IC ${}_{50}$ values and ratios of Bcl-2/Bim (Bcl-xL/Bim or Mcl-1/Bim) was analyzed by linear regression analysis.

Figure 1.

Bcl-2/Bim expression ratio predicts SCLC response to cisplatin. (A) Scatter plot of cisplatin IC ${}_{50}$ values versus the ratios of Bcl-2 (Bcl-xL or Mcl-1)/Bim mRNA expression level in SCLC cell lines. Bcl-2, Bcl-xL, Mcl-1 and Bim mRNA expression levels were from the Cancer Cell Line Encyclopedia (CCLE) ( $n=$ 33 SCLC cell lines). Cisplatin IC ${}_{50}$ values were from Genomics of Drug Sensitivity in Cancer (GDSC) ( $n=$ 33 SCLC cell lines). A linear regression analysis was used to assign a coefficient of determination (R ${}^{2}$ ) and a $P$ value. (B) Protein expression of Bcl-2, Mcl-1 and Bim in 7 SCLC cell lines by western blot analysis. Actin was used as a loading control. The density of the bands was quantified by ImageJ. The ratios of Bcl-2/Bim protein expression level were calculated. The IC ${}_{50}$ values of SCLC cell lines (H526, H82, DMS79, H1963, H446 and H69) were collected from the database of Genomics of Drug Sensitivity in Cancer (GDSC). IC ${}_{50}$ value of H196 cell line is not available (NA) in GDSC database. (C) Scatter plot of cisplatin IC ${}_{50}$ values versus the ratios of Bcl-2/Bim protein expression level in SCLC cell lines. Bcl-2 and Bim protein expression levels were measured by western blot. Cisplatin IC ${}_{50}$ values were from Genomics of Drug Sensitivity in Cancer (GDSC). A linear regression analysis was used to assign a coefficient of determination (R ${}^{2}$ ) and a $P$ value.

Figure 2.

ABT-263 sensitizes SCLC cells to cisplatin or radiation. (A) Cell proliferation assay indicates ABT-263 addition enhances cisplatin or radiation-induced anti-proliferation activity in SCLC. SCLC cells (H526, H69 and H446) were treated with DMSO control, ABT-263, cisplatin, radiation or the combination for 72 hours. Growth inhibition was determined by CellTiter-Glo Luminescent assay after treatment ( ${}^{**}P<$ 0.001, ${}^{***}P<$ 0.0001 and ${}^{****}P<$ 0.00001 compared with cisplatin or radiation treatment alone). (B) ABT-263 combined with cisplatin or radiation dramatically suppressed the ability of SCLC colony formation. SCLC cells (H526, H69 and H446) were treated with DMSO control, ABT-263, cisplatin, radiation or the combination for 24 hours. After treatment, for suspension H526 and H69 cells, the cells were re-plated in a medium with the agarose and then incubated for 3 weeks. For adherent H446 cells, the cells were washed and then incubated for 2 weeks. The number of colonies in the replicated wells ( $n=$ 4) was counted under the microscope. The data represent the mean of colony number $\pm$ SEM ( ${}^{***}P<$ 0.0001 and ${}^{****}P<$ 0.00001 compared with cisplatin or radiation treatment alone). (C) The representative imaging of colony formation assay.

Figure 3.

SCLC sensitization to cisplatin or radiation by ABT-263 was associated with the increased apoptosis. (A) Annexin V apoptotic assay indicates that the addition of ABT-263 enhances cisplatin- or radiation-induced apoptosis. SCLC H446 cells were treated with control, ABT-263 (500 nM), cisplatin (500 nM), radiation (4Gy) or their combination for 48 hours. After treatment, cells were stained with FITC Annexin V and PI, and then flow cytometry was performed. (B) The addition of ABT-263 enhances cisplatin- or radiation-induced PARP cleavage. SCLC cells (H526, H82 and H446) were treated with control, ABT-263 (500 nM), cisplatin (500 nM), radiation (4Gy) or their combination for 24 hours. After treatment, PARP and loading control $\beta$ -actin were detected by western blot. The band density of cleaved PARP and Actin was quantified by ImageJ. The induction of cleaved PARP was calculated (D: DMSO control, A: ABT-263, C: cisplatin, R: radiation). (C) ABT-263 treatment strongly disrupts the interaction of Bim with Bcl-2. H526 cells were treated with control, ABT-263 (500 nM), cisplatin (500 nM), radiation (4Gy) or their combination for 24 hours. After treatment, cells were lysed in immunoprecipitation lysis buffer. Cellular extracts were immunoprecipitated with 1 $\mu$ g anti-Bim antibody. Precipitates were analyzed by western blot to detect Bim and Bcl-2 proteins. The total lysates were also subjected to western blot to detect the expression of Bim and Bcl-2 proteins. $\beta$ -Actin was used as a loading control (D: DMSO control, A: ABT-263, C: cisplatin, R: radiation). (D) Knock-down of Bim is confirmed by western blot. After H69 cells were transfected by Bim siRNA and control siRNA for 48 hours, cellular proteins were collected, and then Bim and Actin was detected by western blot. Protein band intensities were quantified by ImageJ. (E) Knockdown of Bim significantly decreases the growth inhibition of H69 cells treated with the combination of ABT-263 and cisplatin (or radiation). H69 cells were transiently transfected with Bim siRNA and control siRNA for 24 hours. Then, transfected cells were plated in 96-well plate, and treated with DMSO, ABT-263 (50 nM), cisplatin (500 nM), radiation (4Gy) or their combination for 72 hours. Cell proliferation was evaluated by CellTiter-Glo Luminescent assay.

3. Results

3.1 Ratio of Bcl-2/Bim predicts the response of SCLC cells to cisplatin

To identify the predictors of response to cisplatin in SCLC cells, we collected IC ${}_{50}$ data of cisplatin from GDSC database and the gene expression data of Bcl-2 family proteins from CCLE. By matching cell line sensitivity to gene expression data sets, we found the ratios of Bcl-2 to Bim in mRNA level were significantly correlated with cisplatin IC ${}_{50}$ values in SCLC cell lines. However, the ratios of either Bcl-xL or Mcl-1 to Bim were not significantly correlated with cisplatin IC ${}_{50}$ values in SCLC cell lines (Fig. 1A). The mRNA levels of Mcl-1, Bcl-2, Bcl-xL or Bim single molecule were not correlated with cisplatin IC ${}_{50}$ values in SCLC cell lines (Supplementary Fig. S1).

We further examined whether the ratio of Bcl-2/Bim in protein level was correlated with SCLC response to cisplatin. By performing western blot, we detected the protein expression levels of Bcl-2, Mcl-1 and Bim in SCLC cell lines, and quantified band densities by densitometry (Fig. 1B). As shown in Fig. 1C, the ratios of Bcl-2/Bim protein expression were significantly correlated with the IC ${}_{50}$ values of cisplatin in SCLC cell lines. Similar to the mRNA expression data, the ratios of Mcl-1/Bim protein expression were not correlated with the IC ${}_{50}$ values of cisplatin in SCLC cell lines (data not shown). Taken together, the data suggest that the ratio of Bcl-2/Bim may predict SCLC sensitivity to cisplatin.

3.2 ABT-263 sensitizes SCLC cells to cisplatin or radiation

The significant correlation between Bcl-2/Bim ratio and cisplatin sensitivity suggests that Bcl-2 and Bim may be mechanistically associated with the anti-tumor response of cisplatin in SCLC. Thus, we hypothesized that ABT-263, which disrupts the Bcl-2/Bim complex to release Bim for apoptotic induction, was able to potentiate the cytotoxic effect of cisplatin or radiation in SCLC cells. As shown in Fig. 2A, cell viability assay demonstrated that anti-SCLC proliferation activity of cisplatin or radiation was significantly enhanced by ABT-263 addition in H526, H69 and H446 SCLC cells. Furthermore, we performed the analysis of combination index (CI) to determine the synergistic or additive effect of cisplatin and ABT-263 combination. By calculating the combination index (CI), we found that ABT-263 and cisplatin co-treatment exerted synergistic anti-proliferative effect (CI $<$ 1) at low doses in H526 cells (Supplementary Table S1. The combination of ABT-263 and cisplatin induced additive anti-proliferative effect (CI $\sim$ 1) at low doses in H69 cells (Supplementary Table S2). Similarly, multiple doses of ABT-263 and radiation were used to test the combination effect on cell proliferation, indicating that ABT-263 enhanced radiation-induced cell death at all tested doses in H526 and H69 cells (Supplementary Fig. S2).

We further tested the chemo- and radio-sensitization of ABT-263 in SCLC cells by colony formation assay. As shown in Fig. 2B and C, co-treatment of ABT-263 and cisplatin dramatically suppressed colony formation ability of H526, H69 and H446 SCLC cells. Similarly, radiation combined with ABT-263 also strongly reduced colony formation of H526, H69 and H446 SCLC cells. In summary, the data indicate that ABT-263 sensitizes SCLC cells to cisplatin or radiation.

3.3 SCLC sensitization to cisplatin or radiation by ABT-263 was associated with the increased apoptosis

To determine the mechanism of ABT-263-mediated sensitization to cisplatin or radiation, we performed cell apoptotic assay of SCLC cells treated with ABT-263, cisplation, radiation or in combination. Annexin V apoptotic assay indicated that the apoptotic induction of SCLC cells by cisplatin or radiation was remarkablely enhanced by ABT-263 addition (Fig. 3A). Western blot also demonstrated that ABT-263 addition increased cisplatin or radiation-induced PARP cleavage (apoptotic marker) in SCLC cells (Fig. 3B).

We next examined the effect of ABT-263 on the interaction of Bcl-2 and Bim in SCLC cells. Immunoprecipitation assay indicated that the binding of Bcl-2 and Bim was markedly disrupted by ABT-263 treatment alone as well as its combination with cisplatin or radiation (Fig. 3C). To demonstrate whether Bim contributes to apoptosis induced by the combination treatments, we knocked down Bim expression by Bim siRNA (Fig. 3D). Upon Bim knockdown, the inhibition of cell growth by ABT-263 combined with cisplatin or radiation was significantly reduced in H69 cells (vs. control siRNA transfection) (Fig. 3E). The data suggest that ABT-263 disrupts the interaction of Bcl-2 and Bim, and the release of Bim contributes to the increased apoptosis by the combination of ABT-263 with cisplatin or radiation.

To further demonstrate that the disruption of Bcl-2/Bim interaction by BH3 mimetic sensitizes SCLC cells to cisplatin or radiation, we tested ABT-199, a highly potent and selective BCL-2 inhibitor [12]. As shown in Supplementary Fig. S3, cell viability assay demonstrated that the inhibition of cell viability by cisplatin or radiation was significantly enhanced by ABT-199 addition in H526 and H69 cells. Annexin V apoptotic assay indicated that the apoptotic induction of SCLC cells by cisplatin or radiation was also enhanced by ABT-199 addition (Supplementary Fig. S4).

4. Discussion

In the current study, we have used in vitro drug sensitivity data, coupled with gene expression data from public available databases, to develop gene expression predictor reflecting SCLC sensitivity to cisplatin. We identified the ratio of Bcl-2/Bim as a predictor of SCLC sensitivity to cisplatin. It could be potentially applied to SCLC patients to predict who may benefit from cisplatin-based therapy. Despite initially high sensitivity to chemo- and radio-therapy, relapse inevitably develops within months due to the therapeutic resistance. In addition, $\sim$ 30%–40% of SCLC patients still show primary resistance to the gold-standard chemo- and radio-treatments [13]. Therefore, it is worthy to test whether the ratio of Bcl-2/Bim can be used as a predictor of SCLC primary or secondary resistance in a future clinical trial.

ABT-263, a BH3 death domain mimetic, directly binds Bcl-2 to block its interaction with Bim, thereby enabling Bim-mediated induction of apoptosis [14]. The close correlation between Bcl-2/Bim ratio and SCLC response to cisplatin promoted us to examine whether ABT-263 was able to sensitize SCLC cells to cisplatin or radiation. Both cisplatin and radiation induce apoptosis by targeting DNA damage. The interaction between Bcl-2 family anti- and pro-apoptotic proteins determines the cellular sensitivity to DNA damage-induced apoptosis [15]. Indeed, our study found that ABT-263 enhanced cisplatin- or radiation-induced anti-tumor activity through the increased apoptosis in SCLC cells. Our study is consistent with previous studies. Loriot et al. reported that a novel Bcl-2 and Bcl-xL inhibitor S44563, which disrupted the interaction of Bcl-2/Puma interaction, was able to sensitize SCLC cells to radiation [16]. BH3 mimetics (ABT-263 and ABT-737) have been found to be synergized with chemotherapy in various cancer models, including non-small cell lung cancer [17, 18], head and neck cancer [19] and osteosarcoma [20]. Lochmann et al. reported that ABT-199, a BH3 mimetic which only targets Bcl-2 inhibitor, was effective to kill SCLC cells with high Bcl-2 expression [21]. Like ABT-263, our study indicated that ABT-199 enhanced cisplatin or radiation-induced cell death in SCLC cells. In summary, to our knowledge, it is the first study to report a BH3 mimetic sensitizes SCLC cells to chemo-therapy.

In summary, the present study identified a new potential predictor, the ratio of Bcl-2/Bim expression, which might predict SCLC sensitivity to cisplatin. The combination of ABT-263 with cisplatin or radiation in SCLC can lead to marked cellular apoptosis and therefore may improve the efficacy of chemo- and radio-therapy for the treatment of SCLC.

Supplementary data

The supplementary files are available to download from https://dx-doi-org.web.bisu.edu.cn/10.3233/CBM-181692.

sj-docx-1-cbm-10.3233_CBM-181692.docx - Supplemental material

Supplemental material, sj-docx-1-cbm-10.3233_CBM-181692.docx

Footnotes

Acknowledgments

This study was supported by National Natural Science Foundation of China (grant numbers: 81872438, 81672647, 81502632 and 81372214), Natural Science Foundation of Anhui Province (grant number: 1608085MH179), Key Technologies R and D Program of Anhui Province (grant number: 1604a0802103), The Major/Innovative Program of Development Foundation of Hefei Center for Physical Science and Technology (grant number: 2016FXCX006) and the 100-Talent Program of Chinese Academy of Sciences.

Conflict of interest

Authors have no financial/commercial conflicts of interest regarding the study.

Abbreviations

References

Gazdar

A.F.

Bunn

P.A.

and Minna

J.D.

, Small-cell lung cancer: What we know, what we need to know and the path forward, Nat Rev Cancer 17(12) (2017), 765.

Oronsky

Reid

T.R.

Oronsky

and Carter

C.A.

, What’s new in SCLC? A review, Neoplasia 19(10) (2017), 842–847.

Iorio

Knijnenburg

T.A.

Vis

D.J.

Bignell

G.R.

Menden

M.P.

Schubert

Aben

Goncalves

Barthorpe

Lightfoot

Cokelaer

Greninger

van Dyk

Chang

de Silva

Heyn

Deng

Egan

R.K.

Liu

Mironenko

Mitropoulos

Richardson

Wang

Zhang

Moran

Sayols

Soleimani

Tamborero

Lopez-Bigas

Ross-Macdonald

Esteller

Gray

N.S.

Haber

D.A.

Stratton

M.R.

Benes

C.H.

Wessels

L.F.A.

Saez-Rodriguez

McDermott

and Garnett

M.J.

, A landscape of pharmacogenomic interactions in cancer, Cell 166(3) (2016), 740–754.

Yang

Soares

Greninger

Edelman

E.J.

Lightfoot

Forbes

Bindal

Beare

Smith

J.A.

Thompson

I.R.

Ramaswamy

Futreal

P.A.

Haber

D.A.

Stratton

M.R.

Benes

McDermott

and Garnett

M.J.

, Genomics of drug sensitivity in cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells, Nucleic Acids Res 41 (2013), D955–961.

Barretina

Caponigro

Stransky

Venkatesan

Margolin

A.A.

Kim

Wilson

C.J.

Lehar

Kryukov

G.V.

Sonkin

Reddy

Liu

Murray

Berger

M.F.

Monahan

J.E.

Morais

Meltzer

Korejwa

Jane-Valbuena

Mapa

F.A.

Thibault

Bric-Furlong

Raman

Shipway

Engels

I.H.

Cheng

G.K.

Aspesi

, Jr. de Silva

Jagtap

Jones

M.D.

Wang

Hatton

Palescandolo

Gupta

Mahan

Sougnez

Onofrio

R.C.

Liefeld

MacConaill

Winckler

Reich

Mesirov

J.P.

Gabriel

S.B.

Getz

Ardlie

Chan

Myer

V.E.

Weber

B.L.

Porter

Warmuth

Finan

Harris

J.L.

Meyerson

Golub

T.R.

Morrissey

M.P.

Sellers

W.R.

Schlegel

and Garraway

L.A.

, The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature 483(7391) (2012), 603–607.

Thomas

Quinn

B.A.

Das

S.K.

Dash

Emdad

Dasgupta

Wang

X.Y.

Dent

Reed

J.C.

Pellecchia

Sarkar

and Fisher

P.B.

, Targeting the Bcl-2 family for cancer therapy, Expert Opin Ther Targets 17(1) (2013), 61–75.

and Han

, Cisplatin induces expression of drug resistance-related genes through c-jun N-terminal kinase pathway in human lung cancer cells, Cancer Chemother Pharmacol 80(2) (2017), 235–242.

Adams

J.M.

and Cory

, The Bcl-2 apoptotic switch in cancer development and therapy, Oncogene 26(9) (2007), 1324–1337.

Hong

Wang

Deng

Wang

Dai

Yan Lui

V.W.

and Lin

, Combination treatment of RAD001 and BEZ235 exhibits synergistic antitumor activity via down-regulation of p-4E-BP1/Mcl-1 in small cell lung cancer, Oncotarget 8(63) (2017), 106486–106498.

10.

Wang

Hong

Deng

Yan Lui

V.W.

and Lin

, JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer, Oncotarget 8(49) (2017), 86312–86324.

11.

Chou

T.C.

, Drug combination studies and their synergy quantification using the Chou-Talalay method, Cancer Res 70(2) (2010), 440–446.

12.

Souers

A.J.

Leverson

J.D.

Boghaert

E.R.

Ackler

S.L.

Catron

N.D.

Chen

Dayton

B.D.

Ding

Enschede

S.H.

Fairbrother

W.J.

Huang

D.C.

Hymowitz

S.G.

Jin

Khaw

S.L.

Kovar

P.J.

Lam

L.T.

Lee

Maecker

H.L.

Marsh

K.C.

Mason

K.D.

Mitten

M.J.

Nimmer

P.M.

Oleksijew

Park

C.H.

Park

C.M.

Phillips

D.C.

Roberts

A.W.

Sampath

Seymour

J.F.

Smith

M.L.

Sullivan

G.M.

Tahir

S.K.

Tse

Wendt

M.D.

Xiao

Xue

J.C.

Zhang

Humerickhouse

R.A.

Rosenberg

S.H.

and Elmore

S.W.

, ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, Nat Med 19(2) (2013), 202–208.

13.

Byers

L.A.

and Rudin

C.M.

, Small cell lung cancer: Where do we go from here? Cancer 121(5) (2015), 664–672.

14.

S.S.

and Eastman

, BCL2 inhibitors as anticancer drugs: A plethora of misleading BH3 mimetics, Mol Cancer Ther 15(9) (2016), 2011–2017.

15.

Zinkel

Gross

and Yang

, BCL2 family in DNA damage and cell cycle control, Cell Death Differ 13(8) (2006), 1351–1359.

16.

Loriot

Mordant

Dugue

Geneste

Gombos

Opolon

Guegan

Perfettini

J.L.

Pierre

Berthier

L.K.

Kroemer

Soria

J.C.

Depil

and Deutsch

, Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer, Cell Death Dis 5 (2014), e1423.

17.

Matsumoto

Nakajima

Seike

Gemma

and Tanaka

, Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells, Biochem Biophys Res Commun 473(2) (2016), 490–496.

18.

Kim

E.Y.

Jung

J.Y.

Kim

Chang

Y.S.

and Kim

S.K.

, ABT-737 synergizes with cisplatin bypassing aberration of apoptotic pathway in non-small cell lung cancer, Neoplasia 19(4) (2017), 354–363.

19.

Zang

Patel

N.S.

Grandis

J.R.

and Johnson

D.E.

, ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway, Mol Pharmacol 75(5) (2009), 1231–1239.

20.

Zhang

Liu

Zhou

Nie

Cheng

Liu

Dai

and Zhang

, ABT-737 potentiates cisplatin-induced apoptosis in human osteosarcoma cells via the mitochondrial apoptotic pathway, Oncol Rep 38(4) (2017), 2301–2308.

21.

Lochmann

T.L.

Floros

K.V.

Naseri

Powell

K.M.

Cook

March

R.J.

Stein

G.T.

Greninger

Maves

Y.K.

Saunders

L.R.

Dylla

S.J.

Costa

Boikos

S.A.

Leverson

J.D.

Souers

A.J.

Krystal

G.W.

Harada

Benes

C.H.

and Faber

A.C.

, Venetoclax is effective in small-cell lung cancers with high BCL-2 expression, Clin Cancer Res 24(2) (2018), 360–369.